RWA Wealth Partners LLC Has $8.84 Million Stock Position in McKesson Corporation $MCK

RWA Wealth Partners LLC lifted its holdings in McKesson Corporation (NYSE:MCK) by 956.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,438 shares of the company’s stock after purchasing an additional 10,355 shares during the period. RWA Wealth Partners LLC’s holdings in McKesson were worth $8,836,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. State of Wyoming bought a new stake in shares of McKesson during the 2nd quarter worth about $29,000. Hopwood Financial Services Inc. bought a new stake in McKesson during the third quarter worth approximately $31,000. Abound Wealth Management boosted its position in McKesson by 104.3% during the third quarter. Abound Wealth Management now owns 47 shares of the company’s stock worth $37,000 after purchasing an additional 24 shares during the period. Delos Wealth Advisors LLC acquired a new position in McKesson during the second quarter valued at approximately $35,000. Finally, Lynch Asset Management Inc. bought a new position in shares of McKesson in the third quarter valued at approximately $39,000. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the sale, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Maria Martinez sold 349 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the transaction, the director owned 301 shares of the company’s stock, valued at approximately $282,900.87. This represents a 53.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,143 shares of company stock worth $1,046,070 over the last three months. 0.08% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MCK. Wells Fargo & Company raised their target price on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. UBS Group upped their price target on shares of McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Mizuho raised their price target on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. Morgan Stanley reissued an “overweight” rating and set a $966.00 price objective on shares of McKesson in a research report on Thursday, January 29th. Finally, JPMorgan Chase & Co. increased their target price on McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus price target of $943.50.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Large institutional inflows are cited as a key driver behind the stock’s rally, suggesting continued demand from “big money” managers supporting higher valuations. Read More.
• Positive Sentiment: Barclays raised its price target to $1,050 (from $960) and kept an Overweight rating, signaling analyst conviction that shares should remain in favor — this helps push buyers toward the stock. Read More.
• Positive Sentiment: Recent quarterly results beat estimates and McKesson set FY2026 EPS guidance (38.80–39.20), which underpins the bullish analyst revisions and investor inflows. Read More.
• Neutral Sentiment: Industry research lists McKesson among vendors in an expanding Radiology Information Systems market — a longer-term market opportunity but not an immediate stock catalyst. Read More.
• Neutral Sentiment: Brokerage coverage remains skewed to Buy/Outperform (consensus “Moderate Buy”), which supports sentiment but leaves limited immediate upside unless fundamentals surprise further. Read More.
• Negative Sentiment: Faruqi & Faruqi launched a review of McKesson’s proposed share issuance and board conduct, raising governance and dilution concerns that could pressure the stock if the issuance proceeds or litigation follows. Read More.
• Negative Sentiment: An exec director sold ~349 shares (~$328k), a disclosed insider sale that investors may view as minor profit-taking but still worth noting amid governance scrutiny. Read More.
• Negative Sentiment: Some analysts/commentaries (e.g., Seeking Alpha) argue upside could be limited from current levels despite strong results, suggesting some investors may be taking profits. Read More.

McKesson Stock Performance

Shares of MCK opened at $962.65 on Thursday. The company has a 50-day simple moving average of $862.22 and a 200-day simple moving average of $802.17. The firm has a market capitalization of $117.91 billion, a P/E ratio of 27.69, a P/E/G ratio of 1.54 and a beta of 0.40. McKesson Corporation has a 52 week low of $619.48 and a 52 week high of $971.93.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the business earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is 9.43%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.